1. Scrip
  2. >>Therapy Areas
  3. >>Genitourinary

Novartis Bookends October With Two IgAN Successes

 
• By Elizabeth Cairns

A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.    

Novartis HQ
• Source: Novartis

Two out of three ain’t bad, especially when the third is still in play. A hit in Phase III for Novartis AG’s second IgA nephropathy (IgAN) candidate, atrasentan, slots neatly next to the similar showing of iptacopan in the same disease disclosed at the start of the month.

Key Takeaways
  • Atrasentan follows Novartis’s in-house iptacopan with a top-line hit in IgA nephropathy
  • Novartis paid $3.2bn for Chinook, atrasentan’s initial developer
  • Another Chinook asset will report Phase III...

Iptacopan was developed by Novartis itself, but atrasentan was bought in, via the $3.2bn acquisition of Chinook Therapeutics Inc. in June. Today’s result will go some way towards validating...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

More from Therapy Areas

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.